FD	Fabry disease
α-Gal A	α-Galactosidase A
ERT	Enzyme replacement therapy
IRR	Infusion-related reactions
Ig	Immunoglobulin
NK cells	Natural killer cells
IL	Interleukin
NCICTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
Nab	Neutralizing antibodies
ADA	α-agalsidase antibodies
SOB	Shortness of breath
BP	Blood pressure
DC	Dendritic cells
FDA	Food and drug administration
USA	United States of America
TLR	Toll-like receptor
ECL	Electro-chemiluminescent
IRB	Institutional review board